The role of podoplanin inhibitors in controlling oral cancer progression.

In this article, we review the current studies on the role of podoplanin in oral cancer and the potential application of podoplanin inhibitors as a therapeutic agent for oral cancer. The narrative review approach was conducted, providing a comprehensive perspective of related literature. Publications addressing podoplanin and its inhibitors in the context of oral cancer were retrieved from PubMed and Scopus databases. Podoplanin has emerged as a biomarker and therapeutic agent for oral cancer. Numerous studies have reported high podoplanin expression in oral cancer and pre-cancerous lesions compared to normal cells. A specific inhibitor targeting podoplanin may have the potential to prevent oral carcinogenesis via interfering with the pathway of cancerous cells involved in cell proliferation and metastasis. Antibodies, chimeric antigen receptor (CAR)-T cells, cancer-specific mAb (CasMab), synthetic molecules, and lectins are among the materials used as anticancer agents targeting podoplanin. Plant-derived lectins appear to demonstrate a unique advantage against alternative candidates. The use of podoplanin inhibitors in place of existing therapeutic approaches could be a promising and novel approach to the prevention and treatment of oral cancer. Nevertheless, further research is required to investigate the practical application of such inhibitors. • Podoplanin (PDPN) presents as an attractive target for oral cancer therapy. • Antibodies neutralise PDPN-CLEC-2 interaction but present high production costs. • The synthetic molecule, 2CP, is a low-cost adjuvant anti-cancer agent. • Cancer specific mAbs inhibit PDPN without risking toxicity to normal cells. • Lectins show efficient targeting with a unique advantage of oral administration. [ABSTRACT FROM AUTHOR]